Drugs in MeSH Category Analgesics, Opioid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vistapharm Llc	METHADONE HYDROCHLORIDE	methadone hydrochloride	SOLUTION;ORAL	090707-001	Jun 30, 2010	AA	RX	No	No
Btcp Pharma	SUBSYS	fentanyl	SPRAY;SUBLINGUAL	202788-003	Jan 4, 2012		DISCN	Yes	No	9,241,935		Y
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-001	Jan 17, 2017		DISCN	Yes	No	9,216,176		Y
Actavis Elizabeth	OXYMORPHONE HYDROCHLORIDE	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079046-005	Jul 11, 2013		DISCN	No	No
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-002	Apr 26, 2016		RX	Yes	No	9,682,075		Y
Knoa Pharma	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-003	Nov 20, 2014	AB	RX	Yes	No	9,750,703		Y
Mylan Technologies	FENTANYL-25	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	076258-001	Jan 28, 2005	AB	RX	No	No

Last updated: June 29, 2026

Market dynamics and patent landscape for NLM MeSH Class: Analgesics, Opioid (2026)

Opioid analgesics sit at the intersection of high-volume prescribing, intense regulator scrutiny, and dense IP around active ingredients, crystal forms, salts, delivery technologies (including abuse-deterrent formulations), and method-of-use (pain indications, titration strategies, opioid-induced adverse effect management). Patent estates remain fragmented across originator brands, with generics and authorized label expansions often limited by late-expiring formulation and use patents plus FDA Orange Book-driven exclusivity barriers. Litigation is concentrated around Paragraph IV certifications for branded IR/ER opioids, abuse-deterrent technologies, and combination products.

---

What patents protect opioid analgesics in MeSH “Analgesics, Opioid”?

Patent protection for opioid analgesics typically spans four layers:

1. Active pharmaceutical ingredient (API) composition
   Covers opioid drugs, including specific salts, polymorphs, hydrates, and stereochemical variants.

2. Formulation and delivery
   Includes immediate-release (IR), extended-release (ER), and abuse-deterrent (AD) systems. AD protection often covers physical/chemical barriers (e.g., gelling, polymer matrices), tamper-resistant coatings, and extraction-resistant prodrugs.

3. Method-of-use and dosing regimens
   Covers specific titration schedules, dosing intervals, patient populations, or pain syndromes, including breakthrough pain strategies and opioid rotation approaches.

4. Manufacturing/process and kit technology
   Includes process parameters, granulation steps, compression conditions, and multilayer tablet architectures.

How many patents cover opioid analgesics?

The operative number is drug-specific and label-specific. In practice, the patent estate for high-selling ER opioids often reaches 50 to 150 Orange Book-listed patents across multiple Orange Book entries (drug substance, product, and use patents) and multiple jurisdictions. The key market dynamic is that the “last expiring” listed patent frequently is a formulation or use patent, not the API.

Which jurisdictions dominate?

• US (Orange Book + Hatch-Waxman + Paragraph IV) is the primary determinant for generic entry timing.
• EU (SPC + national patents) can extend exclusivity even where US patents look near-term-expiring.
• Canada/UK/Australia follow similar “patent and regulatory linkage” logic, though enforcement and listings differ.

---

When does opioid analgesic exclusivity lose strength in the US?

Two separate calendars matter:

1. FDA exclusivity (fixed by statute)
   Includes NCE/505(b)(1) exclusivity, 3-year exclusivity for new clinical investigations, pediatric exclusivity, and other periods tied to approval pathway and labeling history.

2. Patent expiry (variable by each listed patent)
   Generic barriers persist until the earliest of:

   • patent expiry for a listed patent not successfully challenged,
   • exclusivity expiration tied to the reference listed drug (RLD),
   • and entry conditions imposed by settlements.

Typical US market pattern for opioids

• IR opioids often see earlier generic penetration at the API level, but ER and AD products remain branded longer due to late-expiring formulation/use patents.
• Label changes triggered by post-marketing studies can create new Orange Book listed patents via 505(b)(1) supplements or new proprietary manufacturing/formulation changes, extending the “active” barrier even when the original compound patent has aged out.

---

How do Paragraph IV challenges reshape opioid analgesic entry risk?

Paragraph IV filers target a narrow set of “listed” patents that they can reasonably render invalid or non-infringed. For opioid analgesics, challenges most frequently concentrate on:

• Abuse-deterrent mechanism patents
  Generic AD products must meet AD performance tests and FDA expectations; IP often covers the specific technology and structure.
• ER release profile patents
  Release kinetics and polymer systems are frequently claimed.
• Method-of-use and titration regimens
  Claim scope can be narrowed by label differences, but litigation often hinges on whether the proposed labeling infringes.

Key entry-risk dynamic

Even when a filer “wins” on one patent, entry can be delayed by:

• remaining Orange Book patents in force,
• an adverse court ruling in an additional suit,
• or a settlement that blocks entry until a later date.

---

What is the Orange Book status of major opioid analgesics?

Orange Book listings are product-specific. For market dynamics, the salient point is that “opioid analgesics” is not one asset class but a portfolio of RLDs with different listing density and litigation histories.

What Orange Book listings usually look like for top ER opioids

• Drug substance patents (API)
  Earlier to expire.
• Drug product patents (formulation/AD)
  Often extend the practical barrier.
• Method-of-use patents
  Can be late-expiring and label-driven.

Practical takeaway for market participants

For strategizing generic entry or licensing, the controlling variable is the latest-in-force Orange Book patent that is asserted in litigation and/or the one that a settlement preserves.

---

Which opioid brands have the strongest late-expiring patent estates?

The strongest late-expiring estates generally occur where at least one of the following is true:

• The product has a proprietary abuse-deterrent system (AD mechanism claimed in patents).
• The product has multiple marketed line extensions (new strengths, new dosage forms, or reformulations).
• The product has several method-of-use patents tied to clinical findings and label claims.

In the US, this pattern is typical for ER opioid brands. IR opioids usually have less complex late-stage formulation IP, though combination products and specialized salts can still sustain barriers.

---

What formulations are protected by opioid analgesic patents?

Formulation patents commonly protect:

Abuse-deterrent (AD) technologies

• Physical barriers to tablet crushing
• Gel-forming matrices to reduce extractability
• Layered tablets with tamper-resistant coatings
• Prodrug or chemical transformations reducing misuse routes

Extended-release (ER) delivery

• Polymer matrices with defined release rates
• Pellets/granules and layered ER bead systems
• Osmotic pump-like architectures (where applicable)
• Particle size distributions and blend ratios tied to ER release

Salt forms, polymorphs, and hydrates

• Specific crystalline forms
• Conversion-resistant polymorph control in manufacturing
• Thermodynamic stability regimes and proof of stable solid form

---

What method-of-use patents affect opioid pain indications and dosing?

Method-of-use patents can cover:

• Initiation and titration steps for pain management
• Breakthrough pain regimens
• Use in specific pain categories (chronic pain vs acute pain)
• Strategies for managing opioid-induced adverse effects (depending on the drug and label)

How label changes alter infringement risk

If a generic’s proposed labeling omits the claimed dosing scheme, infringement analysis changes. Companies often litigate whether differences in label language avoid “use” claim coverage.

---

How does FDA regulatory status influence patent leverage for opioid analgesics?

FDA status affects leverage through:

• RLD designation and whether a product is the RLD for its therapeutic family
• Abuse-deterrent labeling requirements and the degree to which generics can claim AB-rated status
• Pathway choice (505(b)(2) vs ANDA) that changes the reliance on clinical data and can trigger different exclusivity and patent listing dynamics

AB-rating matters

Where abuse-deterrent performance is required for substitution at the pharmacy level, AD-related patents and FDA AD labeling interact with commercial viability.

---

What patent litigation affects opioid analgesics most?

Litigation most often centers on:

• Paragraph IV suits for ER opioids and AD products
• Multiple consolidated suits that target different Orange Book patents in parallel
• Settlement agreements that include “payment-for-delay” structures (where they survive regulatory scrutiny and judicial review) and/or stipulated entry dates

Litigation outcomes that move market timing

• Dismissals or summary judgments that narrow asserted claims can accelerate entry.
• Adverse judgments can lock out entry through the remaining patent term.
• Settlements typically define a later entry date than the generic’s theoretical earliest expiration.

---

How do settlement agreements change generic entry timelines for opioids?

Settlements commonly create a defined “designated entry” date tied to:

• patent expiration,
• partial wins (entry allowed for certain strengths/forms earlier),
• or staged launch (specific dosages excluded until later clearance).

This matters commercially because pharmacies and payers rationalize substitution based on product availability across strengths and dosing regimens.

---

What generic entry risks exist for opioid analgesic formulations?

Generic risk in opioids tends to be higher than many other therapeutic areas because:

• Many active opioid labels include strict REMS-related and safety-focused positioning.
• ER and AD products require functional performance beyond chemical equivalence.
• Patent estates often include multiple independent claim sets that survive typical “one-patent” invalidity outcomes.

Manufacturing/IP barriers

• AD generics may need to replicate the claimed physical structure or release mechanics.
• Process patents can constrain manufacturing design-around strategies.

---

How does opioid patent strength compare with other analgesic classes?

Compared with non-opioid analgesics (NSAIDs, acetaminophen combinations, migraine-specific agents), opioid IP is more likely to feature:

• Abuse-deterrent technology protection,
• method-of-use claims tied to chronic pain management,
• and dense Orange Book listing patterns for ER products.

This shifts the balance: even where API patents end, product/formulation and use claims often keep the “effective” barrier alive longer.

---

Market dynamics: pricing power, prescribing controls, and payer behavior

Commercial demand profile

Opioid brands face demand elasticity shaped by:

• conversion to alternative therapies,
• controlled prescribing programs,
• insurer utilization management,
• and substitution pressure from generics once barriers lift.

Patent-driven pricing mechanics

When ER and AD exclusivities persist, the brand maintains:

• formulary positioning,
• rebates and access agreements,
• and payer preference through perceived safety and AD claims.

Once generics or authorized generics enter, pricing typically compresses quickly, though AD-rated competition can reduce substitution volatility if the generic is truly interchangeable in payer workflows.

---

Which companies compete in opioid analgesic generics and authorized products?

Competition generally clusters by:

• ANDA filers focusing on ER and AD barriers,
• authorized generics (when brand originators or licensing structures enable entry),
• and regional distributors focusing on REMS and supply continuity.

The dominant determinant remains Orange Book “last patent” timing for the specific RLD.

---

Timeline framework: how to map opioid market entry events

A practical sequencing model for each target opioid RLD:

1. Last patent expiration (from Orange Book listings)
2. Exclusivity expiration (FDA statutory and pediatric extensions)
3. Paragraph IV suit filing window (date controls 30-month stay where applicable)
4. Trial and appeal milestones (controls ultimate injunction outcomes)
5. Settlement entry date (often the operative commercial trigger)
6. Generic launch readiness (manufacturing scale and AD performance testing if needed)

This sequencing is the basis for revenue exposure modeling for both originator and generic investors.

---

Key takeaways

• Opioid analgesic patent landscapes are driven less by the API and more by late-expiring formulation, abuse-deterrent technology, and method-of-use patents listed in the Orange Book.
• Effective exclusivity for ER and AD opioids often extends well beyond API patent expiry due to layered claims and litigation/settlement-driven entry staging.
• The biggest market timing lever for generic entry is the latest-in-force, litigated Orange Book patent plus any 30-month stay and settlement date.
• Regulatory status and label restrictions influence commercial viability even after legal entry, especially where AD performance and substitution mechanics are central.

---

FAQs

1) What patents usually determine the last entry date for extended-release opioid generics?
Typically product/formulation and method-of-use patents tied to ER release mechanics and abuse-deterrent functionality.

2) Do abuse-deterrent opioid patents block non-AD generic entry?
If the reference product’s FDA labeling and Orange Book patents remain in force for AD-related claims, non-AD versions can be blocked from label substitution or can face infringement risk depending on claim scope.

3) How do settlements in Paragraph IV opioid cases impact launch of specific strengths?
Settlements often allow staged entry where certain strengths or dosage forms launch earlier while other strengths remain blocked until later patent expiry.

4) What regulatory pathway choices change exclusivity and patent linkage for opioid ANDAs?
505(b)(2) and ANDA pathways change the reliance on existing data and can alter exclusivity landscapes and the set of listed patents that matter for entry timing.

5) Are method-of-use patents the most important risk for opioid label copying?
For products with dosing-titration claims, labeling alignment can be a primary infringement vector; generics must match or design around claimed regimens.

---

References (APA)

No sources were provided in the prompt, and no drug-specific Orange Book, litigation docket, or FDA approval-pathway data was included. As a result, no citations can be produced without introducing unverifiable claims.